ABSK011's efficacy and safety performance are revolutionary ...

Moomoo AI Oct 24, 2023 21:39

ABSK011's efficacy and safety performance are revolutionary and exciting, which also shows its significant potential to break the deadlock in second-line liver cancer treatment and reach advanced patients. Despite the variety of PD-1/PD-L1 antibody drugs, small-molecule inhibitors may be insufficient to improve antibody immunotherapy. This indicates that Hwayu Pharmaceutical may usher in a revaluation of its market value.

The ESMO conference announced the two latest R&D results, and Hayu-B (02256), which has strong R&D capabilities, has great valuation potential

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

2975 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4829

Followers

Following

11K

Visitors